Document is current

Article History

Received: 2 December 2025

Accepted: 5 March 2026

First Online: 3 April 2026

Declarations

:

: All the participants provided written informed consent prior to enrollment in Mayo Clinic Bipolar Disorder Biobank. Ethical approval was obtained from Mayo Clinic Institutional Review Board (IRB# 08-008794).

: Not applicable.

: B.S. has received research grant support from Mayo Clinic, the National Network of Depression Centers, Breakthrough Discoveries for Thriving with Bipolar Disorder and NIH. He is a KL2 Mentored Career Development Program scholar, supported by CTSA Grant Number KL2TR002379 from the NCATS. He has received honoraria (to Mayo Clinic) from Elsevier for editing a Clinical Overview on Treatment-Resistant Depression.A.O. receives funding from Mayo Clinic, through a grant Thomas and Elizabeth Grainger Family Charitable Fund at The Chicago Community Foundation and CME travel and honoraria from Carnot Laboratories.F.R.N. is supported in part by NIMH grants K23MH120503 and 1R61MH133770-01A1; is the inventor on a U.S. Patent and Trademark Office patent # 10857356.M.L.B. has received grant support from Breakthrough Discoveries for Thriving with Bipolar Disorder (BD2), Brigham and Women’s Hospital, Harvard Medical School, and receives royalties from Oxford University Press for the sale of his book “The Neuroethics of Biomarkers.” KEB receives honorarium from Breakthrough Discoveries for thriving with Bipolar Disorder (BD2) and as a consultant for Alto Neuroscience and Suven Life Sciences.S.L.M. has received consultation fees and grant support from Axsome Therapeutics.M.A.F. has received grant support from Assurex Health, Baszucki Group, Breakthrough Discoveries for Thriving with Bipolar Disorder (BD2), and Mayo Foundation. He is a consultant for Carnot Laboratories and the American Physician Institute, from which he has received CME/travel supports and honoraria. He also has a financial interest in Chymia LLC through stock ownership and royalties.